{"log_id": 5324308591458945614, "direction": 0, "words_result_num": 26, "words_result": [{"probability": {"variance": 4e-05, "average": 0.997688, "min": 0.966157}, "location": {"width": 792, "top": 220, "height": 48, "left": 225}, "words": "在治疗过程中,一些药物不良反应的治疗可能需要暂停或永久中止阿昔替尼给药"}, {"probability": {"variance": 0.000149, "average": 0.994931, "min": 0.950158}, "location": {"width": 847, "top": 278, "height": 46, "left": 182}, "words": "或降低阿昔替尼剂量(见【注意事项】)。如果需要从5 mg BID开始减量,则推荐剂量"}, {"probability": {"variance": 0.000475, "average": 0.992174, "min": 0.897718}, "location": {"width": 564, "top": 340, "height": 42, "left": 183}, "words": "为3 mg BID。如果需要再次减量,则推荐剂量为2 mg BID"}, {"probability": {"variance": 0.000341, "average": 0.990061, "min": 0.916742}, "location": {"width": 794, "top": 387, "height": 48, "left": 227}, "words": "合用CYP3A4/5强效抑制剂:应避免合用CYP3A4/5强效抑制剂(比如:酮康唑"}, {"probability": {"variance": 7e-06, "average": 0.998292, "min": 0.985615}, "location": {"width": 848, "top": 440, "height": 48, "left": 185}, "words": "伊曲康唑、克拉霉素、阿扎那韦、茚地那韦、奈法唑酮、奈非那韦、利托那韦、沙奎那"}, {"probability": {"variance": 0.002477, "average": 0.979583, "min": 0.702073}, "location": {"width": 845, "top": 495, "height": 48, "left": 188}, "words": "韦、泰利霉素、伏立康唑)。建议选择无CYP3A4/5抑制潜能或有CYP3A4/5微弱抑制潜"}, {"probability": {"variance": 0.000244, "average": 0.993218, "min": 0.916486}, "location": {"width": 846, "top": 550, "height": 49, "left": 187}, "words": "能的药物作为替代的合用药物。尽管尚未在接受CYP3A4/5强效抑制剂的患者中进行阿"}, {"probability": {"variance": 0.002776, "average": 0.98434, "min": 0.67607}, "location": {"width": 847, "top": 604, "height": 49, "left": 187}, "words": "昔替尼剂量调整的研究,但如果必须与CYP3A4/5强效抑制剂合用,建议将阿昔替尼的"}, {"probability": {"variance": 0.000157, "average": 0.994092, "min": 0.945209}, "location": {"width": 849, "top": 658, "height": 49, "left": 187}, "words": "剂量减半,因为预计降低剂量后,阿昔替尼血浆浓度时间曲线下面积(AUC)将调整"}, {"probability": {"variance": 0.000149, "average": 0.994997, "min": 0.930187}, "location": {"width": 846, "top": 713, "height": 48, "left": 190}, "words": "至不与抑制剂合用的AUC范围内。可根据患者安全性和耐受性的个体差异增加或降低"}, {"probability": {"variance": 0.004141, "average": 0.979843, "min": 0.65524}, "location": {"width": 848, "top": 766, "height": 51, "left": 188}, "words": "随后剂量。如果停止与强效抑制剂合用,应将阿昔替尼剂量恢复至(当经过3-5个抑制"}, {"probability": {"variance": 0.001289, "average": 0.987016, "min": 0.780644}, "location": {"width": 845, "top": 819, "height": 54, "left": 190}, "words": "剂半衰期后)开始CYP3A4/5强效抑制剂给药前使用的剂量(见【药物相互作用】和【药"}, {"probability": {"variance": 0.000732, "average": 0.982182, "min": 0.926617}, "location": {"width": 114, "top": 894, "height": 29, "left": 191}, "words": "代动力学】)"}, {"probability": {"variance": 0, "average": 0.903392, "min": 0.903392}, "location": {"width": 183, "top": 855, "height": 70, "left": 841}, "words": "不"}, {"probability": {"variance": 0.015206, "average": 0.945713, "min": 0.610373}, "location": {"width": 274, "top": 944, "height": 34, "left": 236}, "words": "合用强效CYP3A4/5诱导剂"}, {"probability": {"variance": 0.000746, "average": 0.993502, "min": 0.825854}, "location": {"width": 804, "top": 985, "height": 49, "left": 234}, "words": "阿昔替尼与强效CYP3A4/5诱导剂合用可能降低阿昔替尼的血浆浓度(见【药物相"}, {"probability": {"variance": 0.005602, "average": 0.973452, "min": 0.643067}, "location": {"width": 848, "top": 1040, "height": 49, "left": 193}, "words": "互作用】)。建议选择无或仅有最低程度CYP3A4/5诱导可能性的药物作为替代的合用药"}, {"probability": {"variance": 0, "average": 0.999978, "min": 0.999978}, "location": {"width": 27, "top": 1115, "height": 27, "left": 196}, "words": "物"}, {"probability": {"variance": 0.001746, "average": 0.989045, "min": 0.743614}, "location": {"width": 804, "top": 1147, "height": 50, "left": 238}, "words": "尽管尚未在接受强效CYP3A4/5诱导剂的患者中研究阿昔替尼剂量调整,但如果必"}, {"probability": {"variance": 0.001541, "average": 0.989576, "min": 0.747909}, "location": {"width": 847, "top": 1203, "height": 50, "left": 196}, "words": "须与强效CYP3A4/5诱导剂合用,建议逐渐增加阿昔替尼的剂量。据报道,大剂量强效"}, {"probability": {"variance": 0.001775, "average": 0.987885, "min": 0.739007}, "location": {"width": 845, "top": 1257, "height": 53, "left": 198}, "words": "CYP3A4/5诱导剂的最大诱导作用在合用该诱导剂治疗一周内出现。如果阿昔替尼的剂"}, {"probability": {"variance": 1.4e-05, "average": 0.998421, "min": 0.980097}, "location": {"width": 845, "top": 1313, "height": 50, "left": 197}, "words": "量增加,应仔细监测患者的毒性。一些不良药物反应的治疗可能需要暂停或永久中止阿"}, {"probability": {"variance": 0.005967, "average": 0.980186, "min": 0.521402}, "location": {"width": 846, "top": 1368, "height": 52, "left": 198}, "words": "昔替尼治疗,和/或降低阿昔替尼的剂量(见【注意事项】)。如果停止与强效诱导剂合"}, {"probability": {"variance": 0.005746, "average": 0.98524, "min": 0.509763}, "location": {"width": 846, "top": 1425, "height": 52, "left": 199}, "words": "用,应立即将阿昔替尼的剂量恢复至开始强效CYP3A4/5诱导剂给药前使用的剂量(见"}, {"probability": {"variance": 8e-05, "average": 0.994691, "min": 0.971388}, "location": {"width": 129, "top": 1582, "height": 24, "left": 563}, "words": "第3页,共27页"}, {"probability": {"variance": 1.5e-05, "average": 0.995176, "min": 0.987986}, "location": {"width": 43, "top": 1615, "height": 18, "left": 289}, "words": "20150"}], "language": 3}